Category

Biopharmaceutical Fermentation Systems Market Size, Share, And Trends By Product (Upstream, And Downstream), By Application ( Monoclonal Antibodies, Antibiotics, Probiotics, And Others), By End User ( Academic Research Institutions, And Food Industry), And Geography - Forecasts From 2019 To 2024

118 pages
Published on : Jul 2019
Report Code : KSI061612719

Description

Biopharmaceuticals are mostly therapeutic recombinant proteins obtained by biotechnological processes. There has been increased usage of fermentation-derived biopharmaceuticals due to their natural structure, low cost, and better output. Research and development in the field of biopharmaceutical fermentation and launch of new products are expected to drive the growth of the market. Rise of geriatric population and increaing prevalence of chronic diseases is expected to propel the demand for biopharmaceuticals during the forecast period. In addition, increased expenditure on healthcare in different countries is further anticipated to increase the demand for drugs thus leading to market growth opportunites over the next five years. But the availability of substitutes is expected to restrain the growth of the market. The downstream process products segment is expected to have a significant market share due to stringent regulations and the trend of continuous manufacturing & single-use technology. By application, the recombinant protein segment is likely to have a significant market share. Advancement in recombinant technologies, high production capacities and a large number of raw material suppliers is expected to lead to the growth of this market segment. The Asia Pacific segment is expected to offer significant opportunities due to changing economic profiles, rapid urbanization, rise in health care spending and investment, and an increase in the incidence of chronic lifestyle diseases

DRIVERS

Technological advancement

Increased healthcare expenditure

Increase in prevalence of chronic diseases

RESTRAINT

Availability of substitutes

INDUSTRY UPDATE

InFebruary 2019, GE announced its [plan to sell its biopharma unit to Danaher for approximately $21.4 billion

In May, 2017 Dr.Reddy’s announced its plan to expand its biosimilar manufacturing capacity in Hyderabad by 4000 L using GE healthcare’s FlexFactory platform based on single use technology.

SEGMENTATION

The Biopharmaceutical Fermentation System Market has been analyzed through the following segments:

By Product

Upstream products

Downstream products

By application

Recombinant proteins

Monoclonal antibodies

Antibiotics

Probiotics

Others

By end user

Biopharmaceutical companies

Contract manufacturing organizations

Academic research institutions

Food industry

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

Germany

France

United Kingdom

Spain

Others

Middle East and Africa

Saudi Arabia

Israel

Others

Asia Pacific

China

Japan

South Korea

India

Others

OUR CLIENTS